Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications.

Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and

Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs,